

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

06th February, 2026

To,

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. Scrip Symbol: ALKEM
--	--

Sub: Intimation under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Dear Sir/Madam,

This disclosure is being filed pursuant to Regulation 30 of the Listing Regulations, to inform you that the Board of Directors of Alkem Medtech Private Limited (“**AMPL**” or “**Transferee Company**”), a wholly owned subsidiary of Alkem Laboratories Limited (“**Company**”) has, at its meeting held on 6th February, 2026 approved the amalgamation of Alkem Medtech Ortho Private Limited (“**AMOPL**” or “**Transferor Company**”), a wholly owned subsidiary of the Transferee Company, with and into the Transferee Company by way of a scheme of arrangement pursuant to the provisions of Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (including the rules thereunder) (“**Scheme**”), and in compliance with the provisions of the Income Tax Act, 1961.

The Scheme is, *inter alia*, subject to the sanction of the Mumbai bench and Ahmedabad bench of the National Company Law Tribunal (“**NCLT**”) and requisite approvals of the shareholders and/or creditors of the Company, if so directed by the NCLT, and subject to compliance with applicable laws and receipt of other approvals, if required.

However, the equity shares of AMOPL and AMPL are not listed on any stock exchange.

The requisite details as required by the SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, regarding the same, are enclosed herewith as “Annexure A”.

We request you to kindly take the aforesaid on records.

Sincerely,

For Alkem Laboratories Limited

Manish Narang

President- Legal, Company Secretary and Compliance Officer

ANNEXURE A

S. No.	Disclosure Requirements	Brief Particulars												
1.	name of the entity(ies) forming part of the amalgamation/ merger, details in brief such as, size, turnover etc.;	<p>Alkem Medtech Ortho Private Limited is the wholly-owned subsidiary of Alkem Medtech Private Limited (a wholly-owned subsidiary of the Company).</p> <p>The financial details as on 31st March, 2025 are as follows:</p> <table> <tr> <th>Particulars</th><th>Transferor Company</th><th>Transferee Company</th></tr> <tr> <td>Paid-up Equity Share Capital</td><td>3,50,00,000 (Rupees Three Crores Fifty Lakhs only)</td><td>3,80,37,51,800 (Rupees Three Hundred and Eighty Crores Thirty-Seven Lakhs Fifty One Thousand and Eight Hundred only)</td></tr> <tr> <td>Net Worth</td><td>(12,12,47,226) (Negative Twelve Crore Twelve Lakhs Forty Seven Thousand Two Hundred Twenty Six only)</td><td>448,10,94,758 (Four Forty Eight Crore Ten Lakh Ninety Four Thousand Seven Hundred Fifty Eight)</td></tr> <tr> <td>Total Income</td><td>68,17,230 (Sixty Eight Lakh Seventeen Thousand Two Hundred Thirty only)</td><td>8,80,59,457 (Eight Crore Eighty Lakh Fifty Nine Thousand Four Hundred Fifty Seven only)</td></tr> </table>	Particulars	Transferor Company	Transferee Company	Paid-up Equity Share Capital	3,50,00,000 (Rupees Three Crores Fifty Lakhs only)	3,80,37,51,800 (Rupees Three Hundred and Eighty Crores Thirty-Seven Lakhs Fifty One Thousand and Eight Hundred only)	Net Worth	(12,12,47,226) (Negative Twelve Crore Twelve Lakhs Forty Seven Thousand Two Hundred Twenty Six only)	448,10,94,758 (Four Forty Eight Crore Ten Lakh Ninety Four Thousand Seven Hundred Fifty Eight)	Total Income	68,17,230 (Sixty Eight Lakh Seventeen Thousand Two Hundred Thirty only)	8,80,59,457 (Eight Crore Eighty Lakh Fifty Nine Thousand Four Hundred Fifty Seven only)
Particulars	Transferor Company	Transferee Company												
Paid-up Equity Share Capital	3,50,00,000 (Rupees Three Crores Fifty Lakhs only)	3,80,37,51,800 (Rupees Three Hundred and Eighty Crores Thirty-Seven Lakhs Fifty One Thousand and Eight Hundred only)												
Net Worth	(12,12,47,226) (Negative Twelve Crore Twelve Lakhs Forty Seven Thousand Two Hundred Twenty Six only)	448,10,94,758 (Four Forty Eight Crore Ten Lakh Ninety Four Thousand Seven Hundred Fifty Eight)												
Total Income	68,17,230 (Sixty Eight Lakh Seventeen Thousand Two Hundred Thirty only)	8,80,59,457 (Eight Crore Eighty Lakh Fifty Nine Thousand Four Hundred Fifty Seven only)												
2.	whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	<p>The Transferor Company is a subsidiary of the Transferee Company and the Transferee Company is a wholly-owned subsidiary of the Company.</p> <p>However, per the clarification issued by the Ministry of Corporate Affairs vide its General Circular No. 30/ 2014 dated 17th July 2014, a scheme of</p>												

		amalgamation under sections 230-232 of the Companies Act, 2013, will not fall within the purview of related party transaction in terms of Section 188 of the Companies Act, 2013.
3.	area of business of the entity(ies);	<p>The Transferor Company is primarily engaged in the business of manufacturing, producing, trading, importing and exporting all types of equipment, instruments, tools and accessories used in orthopedic surgery and treatment of orthopedic joint implants.</p> <p>The Transferee Company is primarily engaged in the business of manufacturing, importing, exporting, distributing, supplying and marketing of all kinds of medical, surgical, dental, scientific equipment and devices.</p>
4.	rationale for amalgamation/merger;	<p>The Transferor Company is wholly owned subsidiary of the Transferee Company and are engaged in similar business i.e., manufacturing and trading of various medical equipment. The Scheme will <i>inter alia</i> have the following benefits:</p> <ol style="list-style-type: none"> integrate and consolidate business operations, providing a significant impetus to the overall growth and scale of the combined entity; provide a seamless access to a larger pool of assets, including intangible assets, licenses, and intellectual property, leading to greater operational rationalization and organizational efficiency. eliminate duplication of work and rationalization of administrative efforts and functions, thereby enhancing overall business. achieve a significant reduction in overheads, including administrative, managerial, and marketing expenditures. pool financial, technical, and human capital of the Companies and achieve economies of scale and ensure the optimal utilization of resources in the combined entity. allow for a more efficient allocation of capital and enhanced cash flow

		<p>management, strengthening the overall financial position of the combined entity.</p> <p>g) the combined entity will possess a broader and more diversified portfolio of products, strengthening its presence in key therapeutic segments and geographic markets.</p> <p>h) direct access to a combined customer base and optimized distribution networks which will enable the Transferee Company to serve its customers and patients more efficiently.</p> <p>i) restructure and simplify the group structure ensures an optimized corporate holding structure that is better aligned with current business requirements.</p> <p>j) the Scheme provides for a streamlined management structure and improved organizational capability, fostering faster and more effective decision-making.</p> <p>k) facilitate synchronization of efforts to achieve a uniform corporate policy across the combined business.</p> <p>l) reduce of multiplicity of legal and regulatory compliances required to be carried out by separate entities.</p> <p>m) consolidate of business activities will eliminate multiple record-keeping requirements and minimize the administrative burden at a consolidated level.</p>
5.	in case of cash consideration -amount or otherwise share exchange ratio;	Not applicable. As the Transferor Company is a wholly owned subsidiary of the Transferee Company, pursuant to the Scheme coming into effect, all shares held by the Transferee Company in the Transferor Company would stand cancelled and no consideration would pass from the Transferee Company.
6.	brief details of change in shareholding pattern (if any) of the listed entity.	Not applicable. There shall not be any change in the shareholding pattern of the Company pursuant to the Scheme as the Scheme is between subsidiaries of the Company.